Good Medicine Podcast

Good Medicine Podcast

The science behind what makes medicine...good

  1. Why GLP-1s May Not Be the Full Answer | Dr. David & Jeremiah Bearss

    May 19

    Why GLP-1s May Not Be the Full Answer | Dr. David & Jeremiah Bearss

    GLP-1 drugs have changed the conversation around weight loss, but are they the complete solution? In this episode of the Good Medicine Podcast, Dr. David Bearss and Dr. Jeremiah Bearss discuss the benefits and downsides of GLP-1 medications, including how they impact exercise, muscle mass, and long-term weight management. They explore why many people feel poorly while taking these medications, why that can reduce physical activity, and why exercise remains one of the most important components of healthy weight loss. The conversation also looks at what happens after stopping GLP-1 therapy and why regaining weight may come with unintended consequences for body composition. Finally, they discuss AMPK and the idea of developing therapies that could help support the body by mimicking some of the biological signals associated with exercise. Topics covered include: • The benefits and drawbacks of GLP-1 medications• Why muscle loss matters during weight reduction• The future of exercise-signaling therapies like AMPK 🎧 Listen on Spotify and Apple Podcasts📺 Subscribe for more conversations on science, medicine, and innovation. Thank you to our sponsorsBioHive: https://www.biohive.comGalvan: https://galvan.sng.link/D4mh8/oe8k/litt Follow Good Medicine PodcastInsta: https://www.instagram.com/good.medicine.podcast/X: https://x.com/GoodMedicinePodTikTok: https://www.tiktok.com/@good.medicine.podcastLinkedIn: https://www.linkedin.com/company/goodmedicinepodcast/

    57 min
  2. Apr 28

    Is China Taking Over Drug Development? | Dr. David & Jeremiah Bearss

    The global landscape of drug development is changing rapidly. In this episode of the Good Medicine Podcast, Dr. David Bearss and Dr. Jeremiah Bearss discuss the rise of China as a major force in biotech and pharmaceutical innovation. Over the past several years, China has moved from a relatively small player to one of the most active regions for drug development and major deal-making. By changing how drugs are developed, including speed, cost, and efficiency, Chinese companies are increasingly competing on a global scale. They explore what this shift means for U.S. biotech companies, the challenges of competing in a faster and more cost-effective system, and how global partnerships are evolving as a result. The conversation also touches on the pressure facing large pharmaceutical companies, including upcoming patent expirations and the need to replace significant revenue, which may further accelerate global collaboration. Topics covered include: • The shift in biotech deal-making toward China• Competitive pressures facing U.S. companies• The impact of patent expirations on global strategy 🎧 Listen on Spotify and Apple Podcasts📺 Subscribe for more conversations on science, medicine, and innovation. Thank you to our sponsorsBioHive: https://www.biohive.comGalvan: https://galvan.sng.link/D4mh8/oe8k/litt Follow Good Medicine PodcastInsta: https://www.instagram.com/good.medicine.podcast/X: https://x.com/GoodMedicinePodTikTok: https://www.tiktok.com/@good.medicine.podcastLinkedIn: https://www.linkedin.com/company/goodmedicinepodcast/

    35 min
5
out of 5
9 Ratings

About

The science behind what makes medicine...good

You Might Also Like